Amyotrophic Lateral Sclerosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Therapy), By Type (Sporadic ALS, Familial ALS), By Distribution Channel, By Region, And Segment Forecasts, 2026

Description

The global amyotrophic lateral sclerosis treatment market size was valued at USD 746.7 million in 2025 and is projected to grow from USD 790.0 million in 2026 to USD 1,172.3 million in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.5% in 2025. The increasing incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly sporadic ALS, which affects a large number of patients, is a major driver of market growth.

Furthermore, the growing geriatric population, a key risk factor for ALS, is also contributing to the rise in cases. As the population ages, the demand for effective treatment options is likely to increase.

The growing focus on developing targeted therapies and disease-modifying treatments is expected to drive innovation in the ALS treatment landscape. For instance, in December 2025, Biogen announced that long-term results from the Phase 3 VALOR study and its open-label extension demonstrated that early treatment with QALSODY (tofersen) was associated with a slower decline in clinical function, breathing, and muscle strength in patients with SOD1-associated ALS. The findings highlight the increasing progress in precision medicine and gene-targeted therapies aimed at improving outcomes for ALS patients.

Increased awareness and diagnosis are also key drivers of market growth. Rising awareness among patients and healthcare professionals about ALS and available treatment options is boosting diagnosis rates and driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.

Favorable reimbursement policies and expansion of distribution channels are also supporting market growth. In regions such as North America, favorable reimbursement policies for ALS treatments are facilitating access to these therapies and driving market growth. The increasing availability of ALS drugs through hospital pharmacies, retail pharmacies, and online channels is broadening patient access and boosting market growth. As the market continues to evolve, these factors are likely to drive further growth and expansion.

Amyotrophic Lateral Sclerosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyotrophic lateral sclerosis treatment market report by treatment, type, distribution channel, and region:

Treatment Outlook (Revenue, USD Million, 2021 - 2033)

Medication

Riluzole
Edaravone
Others

Stem Cell Therapy

Others

Type Outlook (Revenue, USD Million, 2021 - 2033)

Sporadic ALS

Familial ALS

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

Hospital Pharmacies

Retail Pharmacies

Others

Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America

U.S.
Canada
Mexico

Europe

UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway

Asia Pacific

Japan
China
India
Australia
South Korea
Thailand

Latin America

Brazil
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE
Kuwait

Product Code: GVR-4-68038-001-9

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Amyotrophic Lateral Sclerosis Treatment Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Amyotrophic Lateral Sclerosis Treatment Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Amyotrophic Lateral Sclerosis Treatment Market: Treatment Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Amyotrophic Lateral Sclerosis Treatment Market: Treatment Movement Analysis, 2025 & 2033 (USD Million)
4.3. Medication
- 4.3.1. Medication Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Riluzole
  - 4.3.2.1. Riluzole Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Edaravone
  - 4.3.3.1. Edaravone Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Others
  - 4.3.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Stem Cell Therapy
- 4.4.1. Stem Cell Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Others
- 4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Amyotrophic Lateral Sclerosis Treatment Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Amyotrophic Lateral Sclerosis Treatment Market: Type Movement Analysis, 2025 & 2033 (USD Million)
5.3. Sporadic ALS
- 5.3.1. Sporadic ALS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Familial ALS
- 5.4.1. Familial ALS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Amyotrophic Lateral Sclerosis Treatment Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Amyotrophic Lateral Sclerosis Treatment Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Amyotrophic Lateral Sclerosis Treatment Market: Regional Estimates & Trend Analysis

7.1. Amyotrophic Lateral Sclerosis Treatment Market Share, By Region, 2025 & 2033 (USD Million)
7.2. North America
- 7.2.1. North America Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Europe
- 7.3.1. Europe Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Amyotrophic Lateral Sclerosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation)
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. Biogen
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. BrainStorm Cell Limited
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Amylyx Pharmaceuticals, Inc.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. Ionis Pharmaceuticals, Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. Sanofi
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. Otsuka Pharmaceutical Co., Ltd.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. F. Hoffmann-La Roche Ltd
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. AB Science
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Sun Pharmaceutical Industries Ltd.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives
- 8.4.11. Orion Corporation
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/Strategic Initiatives
- 8.4.12. CORESTEMCHEMON Inc.
  - 8.4.12.1. Participant's Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Product Benchmarking
  - 8.4.12.4. Recent Developments/Strategic Initiatives

Amyotrophic Lateral Sclerosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Therapy), By Type (Sporadic ALS, Familial ALS), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033